Taro Pharma (TARO) Misses Q1 EPS by 62c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Taro Provides Results for Quarter Ended June 2018
August 9, 2018 5:49 PM EDTHAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) today provided unaudited financial results for the quarter ended June 30, 2018.
Quarter ended June 30, 2018 Highlights - compared to June 30, 2017
Net sales of $154.6 million, decreased $6.7 million, or 4.2%, the result of continuing increased competition and the challenging pricing environment; despite an overall increase in volumes of 11.1%. Gross profit of $100.1 million, decreased $16.5 million and as a percentage of net sales, was 64.7% compared to 72.2%. Research and development expenses of $13.3 million decreased $1.3 million.... More